Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
Recursion was able to use its artificial intelligence-enabled drug discovery platform to identify an area of biology to target for the treatment of solid tumors and lymphoma, match it with a drug candidate and move all the way to gaining regulatory approval to begin studies in less than 18 months.
The Food and Drug Administration cleared the investigational new drug application for a phase 1/2 clinical trial of an experimental drug candidate known as REC-1245. The company said the potential market for this treatment could be more than 100,000 patients in the U.S. and European Union. The drug will target RBM39, which Recursion said appears functionally similar to a well-known but hard to target marker known as CDK12 to treat advanced HR-proficient cancers such as ovarian, prostate, breast and pancreatic cancers.
"This is the first program that's come of that," he continued. "It's the first program that really is leveraging many of these new tools that we've built in one unit."
Investment Strategy Breaking News: Investing Health Care Industry Technology Recursion Pharmaceuticals LLC Exscientia PLC Chris Gibson Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UCLA Football: Ethan Garbers Receives Horrible Grade After Bruins Blowout Loss to IndUCLA Bruins quarterback Ethan Garbers receives a terrible rating after facing a major loss against the Indiana Hoosiers.
Read more »
After a study found toxic metals in tampons, lawmakers are pressing the FDA to actMembers of the Democratic Women's Caucus are urging the FDA to address concerns about the safety and regulation of tampons after a study found heavy metals, including lead, in many popular products.
Read more »
After a study found toxic metals in tampons, lawmakers are pressing the FDA to actMembers of the Democratic Women's Caucus are urging the FDA to address concerns about the safety and regulation of tampons after a study found heavy metals, including lead, in many popular products.
Read more »
CDC and FDA find youth vaping drops to lowest level in a decadeNicotine pouches, which are promoted as safer than cigarettes, are growing in popularity, especially with young people. But now, medical organizations are calling on the FDA to halt sales of the popular Zyn brand and similar products while reviewing their safety. NBC News' Vicky Nguyen reports.
Read more »
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP findsU.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19. That's according to an analysis of government data by the Associated Press.
Read more »
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP findsWASHINGTON (AP) — Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019,
Read more »